DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 16, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

Fluidigm Corporation (NASDAQ: FLDM)
Class Period:  February 7, 2019 – November 5, 2019
Lead Plaintiff Deadline:  November 20, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Fluidigm was experiencing longer sales cycles; (2) that, as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

GoHealth, Inc. (NASDAQ: GOCO)
Class Period:  July, 2020 IPO
Lead Plaintiff Deadline:  November 20, 2020

The complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that at the time of the IPO: (1) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (2) GoHealth suffered from a higher risk of customer churn due to its unique business model and limited carrier base; (3) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and its efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (4) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (5) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO.

NextCure, Inc. (NASDAQ: NXTC)
Class Period:   November 5, 2019 – July 14, 2020
Lead Plaintiff Deadline:  November 20, 2020


Shareholders with $100,000 losses or more are encouraged to contact the firm

The complaint filed alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) NextCure possessed NC318 data that showed a lack of efficacy and objective responses; (2) as a result, NC318 was not, in fact, effective in treating most tumor types; (3) as a result, the NC318 application was proving to be limited (if even useful at all); (4) as a result of the foregoing, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com



IMMINENT SHAREHOLDER DEADLINE: BioMarin Pharmaceutical, Inc. Sued for Violations of the Federal Securities Laws; Investors Who Lost Money Should Contact Block & Leviton LLP Before November 24, 2020

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — On August 19, 2020, BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN) stunned the markets when it announced that the U.S. Food and Drug Administration had issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for valoctocogene roxaparvovec (VR) gene therapy for severe hemophilia A. In the CRL, the FDA informed BioMarin that the Company’s BLA was not ready for approval. On this news, BioMarin’s stock fell $41.82 per share, or over 35%, in just one day.

In the CRL, the FDA concluded that “the differences between” BioMarin’s Phase 1/2 study and the Phase 3 study for VR “limited [the FDA’s] ability to rely on the Phase 1/2 study to support durability of effect.” The FDA therefore recommended that BioMarin complete its Phase 3 study (not due to conclude until November 2021) and that BioMarin submit two-year follow-up safety and efficacy data on all study participants.

A lawsuit alleging violations of federal securities laws has been filed against BioMarin and certain of its officers and directors. The suit alleges that beginning on February 28, 2020, BioMarin misled investors about its BLA, namely, that the Company misrepresented the differences between its Phase 1/2 and Phase 3 studies for VR, which limited the reliability of the Phase 1/2 study to support FDA approval. According to the lawsuit, the August 19, 2020 disclosure of the CRL from the FDA shocked the market because of the Company’s previous statements about the BLA and the reliability of the Phase 1/2 study.

The lawsuit was filed in the U.S. District Court for the Northern District of California, and is captioned Tsantes v. BioMarin Pharmaceutical, Inc., et al., No. 20-cv-06719.

If you purchased or acquired shares of BioMarin between February 28, 2020 and August 18, 2020 and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or at https://www.blockleviton.com/cases/bmrn. The deadline to move the Court to be appointed lead plaintiff is November 24, 2020.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com



CIBC Innovation Banking provides debt financing to Yello, Inc.

PR Newswire

CHICAGO, Nov. 16, 2020 /PRNewswire/ – CIBC Innovation Banking today announced it has extended a $15 million credit facility to Yello, a provider of early talent acquisition and recruiting scheduling software. The credit facility will be used to support Yello’s continued growth as it further establishes itself with organizations seeking to hire the best and most diverse talent.

Yello is a Chicago-based portfolio company of JMI Equity and First Analysis. Financing was provided by CIBC Bank USA, CIBC’s US banking subsidiary.

“Yello is in a fast moving and ever changing market. Substantial investment is needed to keep ahead of our customers’ needs while driving growth and a pandemic has made this no easier,” said Corey Ferengul, chief executive officer of Yello. “We are pleased to have CIBC as our partner giving us great flexibility and helping power our growth investments.”

“Yello’s software is further enabling its clients to manage the recruiting process digitally, which has become even more of a priority in the pandemic environment,” said Andrew Schwartz, managing director and market lead, CIBC Innovation Banking. “This important growth financing will support Yello and new CEO Corey Ferengul as they build on Yello’s established reputation in providing recruiting solutions for their customers.”

About Yello

Yello’s early talent acquisition platform allows customers to deliver personalized candidate experiences to every job seeker, resulting in quality hires and faster fills. The centralized platform enables recruiters to collaborate with one another to attract and engage top talent. Key hiring statistics provide meaningful insights that lead to more accurate, data-driven decisions while staying on budget. For more information about Yello, visit https://www.yello.co.

About CIBC

CIBC (NYSE: CM) (TSX: CM) is a leading North American financial institution with 10 million personal banking, business, public sector and institutional clients. CIBC offers a full range of advice, solutions and services in the United States, across Canada and around the world. In the U.S., CIBC Bank USA provides commercial banking, private and personal banking and small business banking solutions and CIBC Private Wealth offers investment management, wealth strategies and legacy planning. Visit us at cibc.com/US.

CIBC Innovation Banking delivers strategic advice, cash management and funding to North American innovation companies at each stage of their business cycle, from start up to IPO and beyond. With offices in Atlanta, Austin, Chicago, Denver, Menlo Park, Montreal, Reston, Toronto and Vancouver, the team has extensive experience and a strong, collaborative approach that extends across CIBC’s commercial banking and capital markets businesses in the U.S. and Canada.

Cision View original content:http://www.prnewswire.com/news-releases/cibc-innovation-banking-provides-debt-financing-to-yello-inc-301173762.html

SOURCE CIBC Bank USA

IMMINENT SHAREHOLDER DEADLINE: Wrap Technologies, Inc. Sued for Violations of the Federal Securities Laws; Investors Who Lost Money Should Contact Block & Leviton LLP Before November 23, 2020

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRTC) purportedly develops security products designed for use by law enforcement and security personnel. In December 2019, Wrap announced that the Los Angeles Police Department had decided to train its officers on Wrap’s “BolaWrap 100,” a handheld remote restraint device.

On September 23, 2020, analyst White Diamond Research stunned the market with its report entitled “Wrap Technologies: Disastrous LAPD BolaWrap Pilot Program Results, No Evidence These Have Been Communicated to Investors.” This report described an August 25, 2020 LAPD analysis, which White Diamond described as revealing that “[o]ver a six-month period, 200 BolaWrap devices in the hands of 1,100 LAPD officers in the field were used only nine times, and only worked once.” On this news, shares of Wrap Technologies common stock fell by over 25% in one day, from their September 22, 2020 close of $8.14 per share to a September 23, 2020 close of $6.07.

A lawsuit alleging violations of federal securities laws has been filed against Wrap Technologies and certain of its officers and directors. The suit alleges that beginning on July 31, 2019, Wrap Technologies misled investors about the purported success of the LAPD trial of the BolaWrap, including that the LAPD officers had provided “great feedback” on their “uses so far” of the BolaWrap. According to the lawsuit, the September 23, 2020 White Diamond Research report shocked the market because of the Company’s previous statements touting the positive result of the LAPD’s BolaWrap trial.

The lawsuit was filed in the U.S. District Court for the Central District of California, and is captioned Cobden v. Wrap Technologies, Inc., et al., No. 20-cv-08760.

If you purchased or acquired shares of Wrap Technologies between July 31, 2020 and September 23, 2020 and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or at https://www.blockleviton.com/cases/wrap. The deadline to move the Court to be appointed lead plaintiff is November 23, 2020.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com 
SOURCE: Block & Leviton LLP
www.blockleviton.com 



NKLA INVESTOR ALERT: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Nikola Corporation

PR Newswire

NEW YORK, Nov. 16, 2020 /PRNewswire/ —  Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of  Nikola Corporation (“Nikola” or the “Company”) (Nasdaq: NKLA) between March 3, 2020 and October 6, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased Nikola securities, and/or would like to discuss your legal rights and options please visit Nikola Shareholder Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

According to the Complaint, the Company made false and misleading statements to the market. Nikola’s founder, Trevor Milton, materially misrepresented the Company’s technology and business. The Company’s profitability and business prospects were massively overstated. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.

On September 10, 2020, Hindenburg Research issued a report titled: “Nikola: How to parlay an Ocean of Lies into a Partnership with the Largest Auto OEM in America.”  In that report Hindenburg claimed that it “gathered extensive evidence-including recorded phone calls, text messages, private emails, and behind-the-scenes photographs detailing dozens of false statements by  the Company’s founder Trevor Milton.”

On this news the Company’s stock price fell during intraday trading on September 10, 2020.

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Nikola securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/nikolacorporation-nkla-shareholder-class-action-lawsuit-stock-fraud-307/apply/ contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nkla-investor-alert-bernstein-liebhard-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-nikola-corporation-301168026.html

SOURCE Bernstein Liebhard LLP

Sukin – Australia’s Most Beloved Natural Skin Care Brand – Continues Its Expansion With the Launch of Its Rosehip Range on Target.com

Sukin makes A-Beauty accessible to everyone. Good for you, your wallet, and the environment too, all Sukin products are 100% vegan, cruelty-free, biodegradable and carbon neutral.

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Sukin, the #1 brand of vegan, cruelty-free and natural skin, hair and body care products in Australia, announced the launch of its Rosehip Range on Target.com. Featuring Australian indigenous ingredients such as Kakadu Plum and Quandong, the Rosehip Range reduces the appearance of fine lines and soothes dry skin. For under $15 each, customers can get the following products on Target.com:

“We call rosehip your soulmate for long-term hydration,” said Cathy Galileos, Sukin Brand Educator. “Paired with our Australian ingredients, rosehip can really do wonders for dry, irritated skin. We’re excited to offer this luxurious and effective line of products on Target.com for the first time.”

In addition to launching its Rosehip Range, Sukin is expanding into an additional 112 Target stores, making affordable and eco-friendly beauty products available to even more consumers across the United States. A leader in the growing A-Beauty trend, Sukin offers sustainable, efficient and accessible skincare, haircare, and body care products inspired by Australia’s laidback lifestyle. In addition to using vegan, Australian native ingredients, Sukin embraces the ecological values that are central to Australian culture by utilizing sustainable packaging and committing to carbon-neutral production methods.

“We are glad that more Americans are taking an interest in adopting A-Beauty’s stress-free, eco-friendly ethos,” said Nigar Zeynalova, Sukin Brand Manager.

Sukin is now available in 422 Target stores nationwide and on Target.com. Shop your Sukin Black Friday deals early. Visit your local Target store during 11/15-11/28 and get the best natural gifts from Sukin for everyone on your shopping list with Buy 1 Get 1 50% off deals.

When Sukin first launched in 2007 in Australia, it was one of the first brands to say “No” to ingredients and processes that can cause harm to you, animals and the environment. In 2008, Sukin expanded its commitment to its eco-values by becoming carbon neutral. Sukin invests in certified projects that offset the company’s carbon emissions and ensures that Sukin’s total carbon output is 100% counteracted, guaranteeing that Sukin does not leave a carbon footprint on this earth. Over the last 10 years, Sukin has offset over 45,000 tons of carbon.

Sukin also partners with Greening Australia, a non-profit tackling Australia’s biggest environmental challenges, to support its Reef Aid program, which helps to improve water quality on the Great Barrier Reef and stop sediment at its source by rebuilding eroding land and restoring vital coastal wetlands.

ABOUT SUKIN

Since its inception in 2007, Sukin has provided natural and effective products that are good for you, your wallet, and the environment. Vegan, cruelty-free, carbon-neutral, grey water safe, and made with recyclable packaging, Sukin was one of the first to say ‘No’ to artificial additives and harsh ingredients that can cause harm to people and the environment. Sukin is available nationwide in the US at select retail stores including Target, Amazon, iHerb, Thrive Market, and SukinNaturals.com.

For more information about Sukin, visit https://sukinnaturals.com/,
Instagram at https://www.instagram.com/sukinskincare_usa/, and
Facebook at https://www.facebook.com/Sukin-Natural-Skincare-USA-101996211294670

ABOUT BWX

BWX is a global, natural beauty company with a portfolio of leading natural brands in Australia, USA, Canada, UK, China, and select other international markets. Founded and headquartered in Victoria, Australia, our expertise in innovation, product development, manufacturing and marketing natural products makes us unique in the beauty industry. Our goal at BWX is to make natural beauty the only choice for people wanting to live a healthy, balanced life, free from unnecessary toxins. We believe everything we need to nourish, rejuvenate and enhance our bodies can be found in nature and our goal is to give people all over the planet a choice for natural personal care without compromising on performance. We want to use our business to inspire the advancement of plant and mineral based science without causing unnecessary harm to the planet. We say NO to testing our products on animals, not because it suits our brand’s commercial goals, but because it is core to our belief system. BWX is a business with purpose and believes in giving. We are actively involved in giving back to causes relating to the environment, social responsibility and projects that empower women.

Contact: Sukin PR
Molly Antos
T: (847) 848-2090
sukin-pr@dadascope.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/268a5769-301b-461c-b9f3-005da3541102

https://www.globenewswire.com/NewsRoom/AttachmentNg/b6c9540c-13a5-4ebe-a009-b1b3a87eec52

https://www.globenewswire.com/NewsRoom/AttachmentNg/b86146b0-a7b5-4edd-991c-6fcc8aa3f03d



Protiviti Recognized as One of the 2020 ‘Best Firms to Work For’ by Consulting Magazine

Employees continue to feel valued and supported during time of global uncertainty

PR Newswire

MENLO PARK, Calif., Nov. 16, 2020 /PRNewswire/ — Global consulting firm Protiviti has been named to Consulting magazine’s ‘Best Firms to Work For‘ list for the seventh consecutive year. The global list is compiled based on the survey responses of consulting firm employees who rate their workplace satisfaction across five categories, including culture, career development, client engagement, compensation and benefits, and firm leadership.

Our goal is to ensure that our people have what they need to be successful at Protiviti.

“It’s very gratifying to receive this award now, during a time of unprecedented global change and uncertainty, because it represents the unwaveringly positive feelings of our people about their careers with us,” said Protiviti President and CEO Joseph Tarantino. “Knowing that our people continue to feel valued and supported is a meaningful endorsement of the many actions we’ve taken over the past several months to maintain our stability and engender confidence for the firm and for our clients as we face the future together.”

“To help our people deal with the effects of the pandemic, we’ve enhanced our robust benefits program with additional offerings such as extra time off to care for children and for family members affected by Covid-19, and increased financial support for back-up caregiver service. We’ve also adopted a highly flexible work approach that allows each individual to factor in the needs of both family and clients,” said Scott Redfearn, executive vice president, global human resources, Protiviti. “Our goal is to ensure that our people have what they need to be successful at Protiviti, no matter how challenging the external environment may be.”

The 2020 Best Firms to Work For were honored with a virtual awards celebration on November 12, 2020. A recording of the online event is available here.

In addition to Protiviti being named to the 2020 Best Firms to Work For list, employees of the firm were recognized with Rising Stars, Top 25 Consultants and Lifetime Achievement awards from Consulting this year.

About Protiviti
Protiviti (www.protiviti.com) is a global consulting firm that delivers deep expertise, objective insights, a tailored approach and unparalleled collaboration to help leaders confidently face the future. Protiviti and its independent and locally owned Member Firms provide clients with consulting and managed solutions in finance, technology, operations, data, analytics, governance, risk and internal audit through its network of more than 85 offices in over 25 countries.

Named to the 2020 Fortune 100 Best Companies to Work For® list, Protiviti has served more than 60 percent of Fortune 1000® and 35 percent of Fortune Global 500® companies. The firm also works with smaller, growing companies, including those looking to go public, as well as with government agencies. Protiviti is a wholly owned subsidiary of Robert Half (NYSE: RHI). Founded in 1948, Robert Half is a member of the S&P 500 index.

Protiviti is not licensed or registered as a public accounting firm and does not issue opinions on financial statements or offer attestation services.

Editor’s note: photos available upon request

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/protiviti-recognized-as-one-of-the-2020-best-firms-to-work-for-by-consulting-magazine-301173757.html

SOURCE Protiviti

Tekla Life Sciences Investors Declares Distribution

Tekla Life Sciences Investors Declares Distribution

BOSTON–(BUSINESS WIRE)–
On November 16, 2020, Tekla Life Sciences Investors declared a distribution of $0.40 per share. The record date for the distribution is November 27, 2020 and the payable date is December 31, 2020. The Fund will trade ex-distribution on November 25, 2020.

This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, December 22, 2020. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.

Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company (“DTC”) as to their full and fractional share requirements by December 21, 2020. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to December 21, 2020.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

For additional information, please visit www.hqcm.com or call (617) 772-8500.

Tekla Capital Management LLC

(877) 855-3434

www.teklacap.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: General Health Science Health Research

MEDIA:

Tekla Healthcare Investors Declares Distribution

Tekla Healthcare Investors Declares Distribution

BOSTON–(BUSINESS WIRE)–
On November 16, 2020, Tekla Healthcare Investors declared a distribution of $0.48 per share. The record date for the distribution is November 27, 2020 and the payable date is December 31, 2020. The Fund will trade ex-distribution on November 25, 2020.

This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, December 22, 2020. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.

Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company (“DTC”) as to their full and fractional share requirements by December 21, 2020. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to December 21, 2020.

Tekla Healthcare Investors (NYSE: HQH) is a closed-end fund that invests in public and private companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

For additional information, please consult www.teklacap.com or call (877) 855-3434.

Tekla Capital Management LLC

(877) 855-3434

www.teklacap.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Millicom to present at Morgan Stanley European Technology, Media & Telecom Conference

Millicom to present at Morgan Stanley European Technology, Media & Telecom Conference

Luxembourg, November 16, 2020 – Millicom International Cellular S.A. (“Millicom”) announces that Millicom’s Chief Executive Officer, Mauricio Ramos, will be presenting at the Morgan Stanley European Technology, Media & Telecom Conference, on Wednesday, November 18 at approximately 6:20 pm (Stockholm) / 5:20 pm (London) / 12:20 pm (Miami).

A live webcast and replay of the presentation will be available at the following link.

-END-

For further information, please contact

Press:


Vivian Kobeh, Corporate Communications Director
+1 786-628-5300
press@millicom.com

 

 

 

Investors:

Michel Morin, VP Investor Relations
1 786-628-5270
investors@millicom.com

 

Sarah Inmon, Investor Relations Senior Manager
+1 786-628-5303
investors@millicom.com

About Millicom

Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle® services through its principal brand, TIGO. As of December 31, 2019, Millicom operating subsidiaries and joint ventures employed more than 22,000 people and provided mobile services to approximately 52 million customers, with a cable footprint of more than 11 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg.

 

Attachment